Display options
Cite
Kim JM, Back MK, Yi HS, et al. Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Diabetes Metab J. 2016;40(1):70-8doi: 10.4093/dmj.2016.40.1.70.
Kim, J. M., Back, M. K., Yi, H. S., Joung, K. H., Kim, H. J., & Ku, B. J. (2016). Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Diabetes & metabolism journal, 40(1), 70-8. https://doi.org/10.4093/dmj.2016.40.1.70
Kim, Ji Min, et al. "Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia." Diabetes & metabolism journal vol. 40,1 (2016): 70-8. doi: https://doi.org/10.4093/dmj.2016.40.1.70
Kim JM, Back MK, Yi HS, Joung KH, Kim HJ, Ku BJ. Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Diabetes Metab J. 2016 Feb;40(1):70-8. doi: 10.4093/dmj.2016.40.1.70. PMID: 26616597; PMCID: PMC4768053.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab J. 2016 Feb;40(1):70-8. doi: 10.4093/dmj.2016.40.1.70.

Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia.

Diabetes & metabolism journal

Ji Min Kim, Min Kyung Back, Hyon Seung Yi, Kyong Hye Joung, Hyun Jin Kim, Bon Jeong Ku

Affiliations

  1. Research Center for Endocrine and Metabolic Diseases, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
  2. Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
  3. Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea. [email protected].
  4. Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea. [email protected].

PMID: 26616597 PMCID: PMC4768053 DOI: 10.4093/dmj.2016.40.1.70

Abstract

BACKGROUND: Elevated serum levels of growth differentiation factor-15 (GDF-15) are associated with type 2 diabetes. Therefore, the effects of atorvastatin on metabolic parameters and GDF-15 levels in patients with type 2 diabetes and dyslipidemia were evaluated.

METHODS: In this prospective randomized trial from February 2013 to March 2014, 50 consecutive type 2 diabetic patients with a low density lipoprotein cholesterol (LDL-C) levels ≥100 mg/dL were enrolled. The patients were divided into two groups based on the amount of atorvastatin prescribed, 10 mg/day (n=23) or 40 mg/day (n=27). The effect of atorvastatin on metabolic parameters, including lipid profiles and GDF-15 levels, at baseline and after 8 weeks of treatment were compared.

RESULTS: The baseline metabolic parameters and GDF-15 levels were not significantly different between the two groups. After 8 weeks of treatment, the total cholesterol (TC) and LDL-C levels were significantly decreased in both groups. The mean changes in TC and LDL-C levels were more significant in the 40 mg atorvastatin group. The GDF-15 level was decreased in the 10 mg atorvastatin group, from 1,460.6±874.8 to 1,451.0±770.8 pg/mL, and was increased in the 40 mg atorvastatin group, from 1,271.6±801.0 to 1,341.4±855.2 pg/mL. However, the change in the GDF-15 level was not statistically significant in the 10 or 40 mg atorvastatin group (P=0.665 and P=0.745, respectively).

CONCLUSION: The GDF-15 levels were not significantly changed after an 8-week treatment with atorvastatin in type 2 diabetic patients.

Keywords: Atorvastatin; Dyslipidemias; Growth differentiation factor 15; Type 2 diabetes

References

  1. Nat Rev Drug Discov. 2014 Jun;13(6):465-76 - PubMed
  2. Diabetes Metab J. 2014 Dec;38(6):472-9 - PubMed
  3. Physiol Genomics. 2007 Apr 24;29(2):118-27 - PubMed
  4. Eur J Endocrinol. 2012 Nov;167(5):671-8 - PubMed
  5. J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60 - PubMed
  6. N Engl J Med. 2001 Jun 28;344(26):1959-65 - PubMed
  7. PLoS One. 2013 Dec 02;8(12):e78797 - PubMed
  8. Curr Heart Fail Rep. 2012 Dec;9(4):337-45 - PubMed
  9. PLoS One. 2013 Jun 14;8(6):e65549 - PubMed
  10. Growth Factors. 2011 Oct;29(5):187-95 - PubMed
  11. JAMA. 2001 Jul 4;286(1):64-70 - PubMed
  12. Biomarkers. 2010 Dec;15(8):671-6 - PubMed
  13. Clin Chem. 2013 Nov;59(11):1550-2 - PubMed
  14. Endocrinology. 2009 Apr;150(4):1688-96 - PubMed
  15. QJM. 2002 Jun;95(6):339-41 - PubMed
  16. Atherosclerosis. 2004 Nov;177(1):161-6 - PubMed
  17. Br J Pharmacol. 2014 Aug;171(15):3741-53 - PubMed
  18. Lancet. 2008 Jan 12;371(9607):117-25 - PubMed
  19. Kidney Int. 2003 Jan;63(1):12-23 - PubMed
  20. Cell Tissue Res. 2004 Nov;318(2):325-33 - PubMed
  21. Circulation. 2011 May 17;123(19):2101-10 - PubMed
  22. J Biol Chem. 2014 Apr 4;289(14):10084-94 - PubMed
  23. J Atheroscler Thromb. 2014;21(10):997-1010 - PubMed
  24. Mol Cancer Ther. 2005 Mar;4(3):487-93 - PubMed
  25. Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):203-10 - PubMed
  26. Circulation. 2003 Oct 28;108(17):2113-20 - PubMed
  27. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):109-14 - PubMed
  28. PLoS One. 2014 May 09;9(5):e97009 - PubMed
  29. Toxicol Mech Methods. 2005;15(2):61-92 - PubMed
  30. Clin Chem. 2012 Jan;58(1):172-82 - PubMed
  31. Lancet. 2005 Oct 8;366(9493):1267-78 - PubMed
  32. Eur Heart J. 2009 Oct;30(19):2346-53 - PubMed
  33. Eur J Endocrinol. 2009 Sep;161(3):397-404 - PubMed
  34. Endocrinol Metab (Seoul). 2014 Dec 29;29(4):443-9 - PubMed
  35. Clin Chem. 2013 Nov;59(11):1613-20 - PubMed
  36. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9 - PubMed
  37. J Clin Invest. 1995 May;95(5):2409-15 - PubMed
  38. Physiol Genomics. 2008 Jun 12;34(1):112-26 - PubMed

Publication Types